7-氧杂-1-氮杂螺[4.4]壬烷-6-酮,4-乙烯基-1-甲基-,(4R,5R)-rel- | 265987-99-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 7-氧杂-1-氮杂螺[4.4]壬烷-6-酮,4-乙烯基-1-甲基-,(4R,5R)-rel-
• 英文名称: tert-butyl N-[(1R,2R)-2-aminocyclopropyl]carbamate
• CAS: 265987-99-3
• 化学式: C₈H₁₆N₂O₂
• mdl: MFCD11099666
• 分子量: 172.227
• InChiKey: XDHLWTHTPXBYLH-PHDIDXHHSA-N

物化性质

• 沸点：
  266.8±29.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-氧杂-1-氮杂螺[4.4]壬烷-6-酮,4-乙烯基-1-甲基-,(4R,5R)-rel- 在 bis(1,5-cyclooctadiene)diiridium(I) dichloride 、 三乙胺 、 1,2-双(二苯基膦)乙烷 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 1.75h， 生成 (R)-1-phenylethyl (3R,4S)-3-azido-1-(N-((rac)-trans-2-((tert-butoxycarbonyl)amino)cyclopropyl)sulfamoyl)-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propyl)pyrrolidine-3-carboxylate
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'ARGINASE

  摘要：

  本发明涉及杂环化合物作为精氨酸酶抑制剂，特别是一种由化学式（I）表示的化合物，或其药学上可接受的盐、立体异构体或互变异构体，或其前药，以及包含该化合物的药物组合物。

  公开号：

  WO2019120296A1
• 作为产物：
  描述：

  (+/-)-(trans)-N,N'-bis(tert-butyloxycarbonyl)-1,2-cyclopropanediamine 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 以80%的产率得到7-氧杂-1-氮杂螺[4.4]壬烷-6-酮,4-乙烯基-1-甲基-,(4R,5R)-rel-
  参考文献：
  名称：

  Benzamides derived from 1,2-diaminocyclopropane as novel ligands for human D 2 and D 3 dopamine receptors

  摘要：

  Benzamides (3a-f) derived from 4-amino-5-chloro-2-methoxybenzoic acid and either cis or trans 1,2-diamino cyclopropane were synthesised and were evaluated in binding assays employing, bovine striatal D-2 receptors, recombinant human hD(2) and hD(3) receptors expressed in CHO cells and rat, cortical 5-HT3 and striatal 5-HT4 receptors. The cis and trans isomers of the derivatives were isolated and characterised. The results demonstrated the superiority of the cis conformers over the trans conformers in dopamine receptor binding assays (K-i hD(2) = 13.4 and 6.9 nM and K-i hD(3) = 17.7 and 4.5 nM for the cis-3b and cis-3f compounds, respectively; K-i hD(2) = 816 and >1000 nM and K-i hD(3) = 469 and >1000 nM for the corresponding trans-3b and trans-3f compounds respectively). The cis compounds are folded: the benzamide group and the basic nitrogen atom were in a syn relationship. Compound 3f can be superimposed with a conformation of the tropane derivative, BRL 25594, having the benzyl group in an axial position to give a suitable fit, indicating that both compounds may have a common binding site in the dopamine receptor. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00281-3

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'ARGINASE
  申请人：GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD

  公开号：WO2019120296A1

  公开（公告）日：2019-06-27

  The present invention relates to heterocyclic compounds as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceutical composition comprising said compound.

  本发明涉及杂环化合物作为精氨酸酶抑制剂，特别是一种由化学式（I）表示的化合物，或其药学上可接受的盐、立体异构体或互变异构体，或其前药，以及包含该化合物的药物组合物。
• CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
  申请人：LEHMANN-LINTZ Thorsten

  公开号：US20110217311A1

  公开（公告）日：2011-09-08

  The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2 a or Mnk2 b ) and/or variants thereof.

  本发明涉及新型噻吩并嘧啶化合物，其一般公式，包含这些化合物的药物组合物，以及它们在预防和/或治疗可通过抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）及其变体的激酶活性而影响的疾病中的治疗用途。
• SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES
  申请人：Pouzet Pascale

  公开号：US20110021501A1

  公开（公告）日：2011-01-27

  The invention relates to new piperidino-dihydrothienopyrimidines of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 , R 3 and R 4 may have the meanings given in claim 1 , as well as pharmaceutical compositions which contain these compounds. These new piperidino-dihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.

  本发明涉及通式1的新哌啶二氢噻吩并嘧啶类化合物及其药理上可接受的盐，其中X为SO或SO2，优选SO，并且其中R1、R2、R3和R4可具有权利要求1中所述的含义，以及含有这些化合物的药物组合物。这些新哌啶二氢噻吩并嘧啶类化合物适用于治疗呼吸系统或胃肠道疾病、关节、皮肤或眼睛的炎症性疾病、周围或中枢神经系统疾病或癌症。
• Substituted piperazino-dihydrothienopyrimidines
  申请人：Pouzet Pascale

  公开号：US08754073B2

  公开（公告）日：2014-06-17

  Piperidinodihydrothienopyrimidines of formula 1 wherein X is SO or SO2 (preferably SO), and R1, R2, R3, and R4 may have the meanings given in the disclosure and claims, pharmacologically acceptable salts thereof, and pharmaceutical compositions containing these compounds. These piperidinodihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system, or cancers.

  公式1中的Piperidinodihydrothienopyrimidines，其中X为SO或SO2（优选为SO），而R1、R2、R3和R4可能具有公开说明和权利要求中所给的含义，其药理学上可接受的盐以及含有这些化合物的制药组合物。这些Piperidinodihydrothienopyrimidines适用于治疗呼吸系统或消化系统的不适或疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统的疾病或癌症。
• 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20140243336A1

  公开（公告）日：2014-08-28

  The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了某些含有2-吡啶基羧酰胺的化合物，其化学式为(I)，或其药学上可接受的盐，其中A和B如本文所定义。本发明还提供了包括这些化合物的药物组合物，并且提供了使用这些化合物治疗由脾脏酪氨酸激酶（Syk）介导的疾病或症状的方法。